Abstracts should be submitted only through the WL-7 website. Other means of submission such as fax or e-mail will not be accepted. All abstracts must be submitted and presented in English. Abstracts should contain original materials.

Inclusion of tables, charts and other graphics is not recommended in the abstract.

All abbreviations must be defined at the first appearance in the text (do not define abbreviations in the title).

Authors may suggest a topic under which they wish their abstract to be reviewed (see below).

An e-mail address must be provided for acknowledging the receipt of your submission with a reference number. The reference number will be used for all future correspondence. Authors will be notified about the acceptance by January 31, 2021, via e-mail.

Abstracts are subject to review by more than one member of the Scientific Committee for inclusion in the program and for oral/poster presentation. The corresponding authors will be informed of the decision by the WL-7 organizers via e-mail communication (therefore it is essential to provide your correct e-mail address). The decision will be posted on the website as well. Full instructions for abstract preparation and presentation will be provided in the website.

All accepted abstracts will be included in an abstract book, which will be in the website and given to all registered participants as a hard copy and CD.

October 31th, 2020. Selected topics for Abstract submission:

  1. Social and demographic change of leishmaniasis: from the first WorldLeish to today
  2. Implementation of strategies for increasing access to  treatment
  3. Impact of the armed conflict, displacement and refugees in the occurrence of leishmaniasis: how big is the problem?
  4. Understanding Leishmania: From the «omics» to the clinic
  5. The hope of a prophylactic vaccine
  6. Integrated Management of leishmaniasis: Lessons Learned from Existing Practice and Field Research.
  7. The human in the transmission of Leishmania spp to sand flies: What’s new?
  8. Is the prevention of canine leishmaniasis enough for the control of human zoonotic visceral leishmaniasis?
  9. Leishmaniasis control: what is done and has to be done.
  10. Immunological perspectives of leishmaniasis: beyond the Th1/Th2 paradigm
  11. How to achieve mental health and psychosocial well-being in leishmaniasis
  12. Strategies for the elimination of barriers to diagnosis
  13. Future prospects in the treatment of cutaneous leishmaniasis form
  14. Health and social information systems in support of local health planning: issues and challenges.
  15. Burden of social stigma in cutaneous leishmaniasis
  1. New Perspective on Improving Treatment Efficacy in canine leishmaniasis
  2. Geo-climatic factors and emerging of new foci of leishmaniasis
  3. Drug discovery: Future directions
  4. Leishmaniasis in  non-HIV immunosuppressed patients
  5. Biomarkers for leishmaniasis
  6. Clinical management of visceral leishmaniasis patients
  7. Existing knowledge gaps in cutaneous and mucosal Leishmaniasis
  8. Burden of social stigma in cutaneous leishmaniasis
  9. Impact of RNA virus in the epidemiology of leishmaniasis
  10. Epidemiological Trend of Cutaneous and mucosal Leishmaniasis in Endemic Foci by regions
  11. Public awareness and attitudes towards cutaneous leishmaniasis
  12. Molecular markers for strain typing of Leishmania species: which are truly useful and in which regions or conditions.
  13. New trends and challenges in the Diagnosis of Leishmaniasis
  14. Strategies to unify the Dx and species identification in Leishmaniasis
  15. Computational approaches applied in drug discovery

(Prepare abstract by using the template provided in the web site according to the instructions for the format of the title, authorship, affiliation, text (not to exceed 2500 characters plus space within the space limit).